COMPANY PROFILE

Sanofi

Explore full profile

A global integrated healthcare leader discovers, develops and distributes therapeutic solutions

Paris, FranceFounded 1973Health

Valuation $117B Market cap · 2026

Revenue $52B Latest reported FY

EBITDA $16B Latest reported FY

About Sanofi

Sanofi is a global healthcare company dedicated to providing innovative treatments and life-saving vaccines to millions of people worldwide. Operating in the pharmaceutical and biotechnology sectors, Sanofi focuses on research and development (R&D) to address unmet medical needs in areas such as immunology, oncology, rare diseases, and vaccines. The company serves a diverse range of clients, including patients, healthcare professionals, and governments, by offering a broad portfolio of prescription medicines, over-the-counter products, and vaccines.

Sanofi's business model revolves around extensive R&D efforts, strategic partnerships, and a robust pipeline of new products. The company invests heavily in scientific innovation to develop breakthrough therapies and improve existing treatments. Revenue is generated through the sale of pharmaceutical products and vaccines, as well as through collaborations and licensing agreements with other healthcare entities.

Sanofi operates in a highly competitive market, with a strong presence in both developed and emerging markets. The company leverages its global reach and expertise to navigate regulatory environments and deliver its products to those in need. By focusing on patient-centric solutions and maintaining a commitment to quality and safety, Sanofi aims to improve health outcomes and enhance the quality of life for people around the world.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 1973
Headquarters: Paris, France
Listing: IPO 2002
Employees: 84,954
Open positions: None listed
Dealroom signal: 26.7/100
Industry: Health
Sector: Health, Health Care Information Technology, Diabetes, Healthcare Services, Biotechnology, Cardiology and cardiovascular, B Corp, Horizon Europe, observatoire healthtech
Business model: Manufacturing
Client focus: b2b
Investment activity: 89 companies, latest Sep 2026
Capital deployed: $4.2B
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANT✓Other financing	Sep 2026	$440M	—	European Commission · Germany	↗
POST IPO DEBT✓Debt	Oct 2025	$3B	—	Undisclosed	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$52B	+2%	$16B	30.9%	$8.2B	15.7%	$8.6B
2025	$51B	+5.5%	$17B	33.8%	$8.6B	16.7%	$8.6B
2024	$49B	-4.6%	$15B	29.9%	$6.1B	12.6%	$8.1B
2023	$51B	+2.3%	$17B	32.7%			$7.4B
2022	$50B	+15.9%	$15B	30.3%
2021	$43B	+4.8%	$12B	27.5%
2020	$41B	—	$11B	26.1%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Sanofi website traffic

Latest recorded traffic for Sanofi is 860K monthly website visits, up 104.8% over the last three months. Sanofi's team grew 0% over the past year.

Latest monthly visits860K 3-month web change+104.8% 1-year team growth0%

Monthly website visitsOct 2014–Feb 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GEGenfitDevelops drugs for the prevention and treatment of cardiometabolic and neurodegenerative diseases	Loos, France	Operational	210	$45M	$484M
IMImpeto MedicalImpeto Medical develops a non-invasive technology that analyzes the activities of sweat glands to detect early stages of diabetes.	Paris, France	Acquired
BOBOYDSenseBOYDSense - Health monitoring made simple powered by breath	Toulouse, France	Operational
IQIQVIAHelping healthcare clients make better, more insightful decisions and discover breakthroughs using human data science	Durham, United States	Acquired
NENEURALTIDEDedicated to the development of a medical device for the treatment of ischemic strokes	Paris, France	Operational
IMInVera MedicalDeveloping the world's first pain-free and effective medical device treatment for all chronic venous disease sufferers	Galway, Ireland	Operational
GTGradient Denervation TechnologiesDeveloping a novel endovascular, catheter-based technology to treat pulmonary hypertension	Paris, France	Operational
ESETISENSE SASDeveloped a non-invasive cardiac and respiratory flow-metering technology to monitor cardiorespiratory function in a non-invasive way	Lyon, France	Operational